Emerging therapeutic options for managing diabetic kidney disease
Readers of this journal need no reminder of the scale of the diabetes pandemic, but a reminder of the population level data is still staggering. Current estimates are that one of every eleven adults worldwide has diabetes, resulting in annual direct costs approaching $1 trillion [1,2]. Combating this public health dilemma of modern civilization is a focus of a number of international governing bodies. Given that diabetes is already the primary cause of end-stage kidney disease across the globe, the nephrology community is taking a leading role in organizing against this challenge . Mexico City was an especially appropriate location for the recently held World Congress of Nephrology 2017 focusing on diabetic kidney disease (DKD). It is the capital of one of the most severely affected countries, where one of every seven adults is afflicted with diabetes, and where diabetes has been the leading cause of mortality for years . Any chance of defeating the diabetes pandemic will certainly require a multipronged approach targeting the entire lifecycle: from fetal development, to overweight and obesity in childhood and adulthood, to prevention of diabetic complications and managing organ dysfunction when it occurs.